NCT00338143已完成3 期
A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,200
研究概览
简要总结
This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy and may also be receiving topical therapies, PUVA, or UVB phototherapy during the efalizumab treatment period.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Plaque psoriasis covering >=10% of total BSA
- •Plaque psoriasis diagnosed for at least 6 months
- •In the opinion of the investigator, a candidate for systemic therapy for psoriasis
- •18-75 years old
- •Body weight <=125 kg
- •For women of childbearing potential, use of an acceptable method of contraception to prevent pregnancy and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study and for 3 months after the last dose of efalizumab
排除标准
- •Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis
- •Pregnancy or lactation
- •Clinically significant psoriasis flare during screening or at the time of enrollment
- •History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection
- •History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •Seropositivity for hepatitis B or C virus
- •Seropositivity for human immunodeficiency virus (HIV)
- •History of active tuberculosis (TB) or currently undergoing treatment for TB
- •Presence or history of malignancy within the past 5 years, including lymphoproliferative disorders
- •Previous treatment with efalizumab (anti-CD11a)
- •Diagnosis of hepatic cirrhosis, regardless of cause or severity
- •Hospital admission for cardiovascular or pulmonary disease within the last year
- •History of severe allergic or anaphylactic reactions to monoclonal antibodies or fusion proteins, which contain an Ig Fc region (e.g., etanercept, alefacept)
- •History of treatment with lymphocyte-depleting monoclonal antibodies or immunoadhesion molecules (e.g., anti-CD4, CTLA4-Ig, alefacept)
- •White blood cell (WBC) count < 4000/uL or > 14,000/uL
- •Hepatic enzymes >= 3 times the upper limit of normal
- •Creatinine >= 2 times the upper limit of normal
- •Use of experimental drugs or treatments within 30 days or five half-lives, whichever is longer, prior to the first dose of efalizumab
- •Use of a live virus or live bacteria vaccine in the 14 days prior to the first dose of efalizumab
- •Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug or would significantly interfere with the subject's ability to comply with the provisions of this protocol
- •Restrictions and/or directions apply to the following treatments during specified time periods prior to and during the efalizumab treatment period: Systemic therapy for psoriasis (biologic and non-biologic); Systemic immunosuppressive drugs for conditions other than psoriasis; Live virus or bacteria vaccine (these vaccines may include, but are not limited to, measles, mumps, rubella, polio, BCG, yellow fever, and TY21a typhoid); Other vaccines or allergy desensitization injections
研究者
相似试验
已完成
3 期
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01941095Hoffmann-La Roche100
已完成
3 期
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerBreast CancerNCT02019277Hoffmann-La Roche50
已完成
3 期
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Squamous Non-Small Cell LungNCT02367781Hoffmann-La Roche723
进行中（未招募）
3 期
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILDPulmonary Hypertension Due to Lung DiseasesPulmonary Arterial HypertensionNCT04691154Liquidia Technologies, Inc.28
Unknown
3 期
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.Hemophilia ANCT03947320Sinocelltech Ltd.70